Intrathecal inflammation precedes development of Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 74, Issue 9, 2003, Pages 1200-1205

  Tarkowski, E ^a   Andreasen, N ^b   Tarkowski, A ^a   Blennow, K ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK ASSESSMENT; RISK FACTOR; SENILE PLAQUE; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CENTRAL NERVOUS SYSTEM; COGNITION DISORDERS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; INTERLEUKIN-1; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SENILE PLAQUES; TAU PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141740742     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.9.1200     Document Type: Article

References (44)

1. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci 1985;82:4245-9.
2. Banati RB, Beyreuter K. Alzheimer's disease. In: Kettenman H, Ransom BR, eds. Neuroglia. New York: Oxford University Press, 1995:1027-43.
3. McGeer PL, Akiyama H, Itagaki S, et al. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989;16:516-27.
4. McGeer PL, Itagaki S, Tago H, et al. Reactive microglia in patients with senile dementia of Alzheimer type ore positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987;79:195-200.
5. St Pierre BA, Merill JE, Dopp JM. Effects of cytokines on the CNS cells: glia. In: Ransohoff RM, Benveniste EN, eds. Cytokines and the CNS. Boca Raton, FL: CRC Press, 1996:151-68.
6. Bauer J, Ganter U, Strauss S, et al. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. 45th forum in Immunology. Res Immunol 1992;143:650-7.
7. Griffin WST, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989;86:7611-15.
8. Dickson DW, Lee SC, Mattiace LA, et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993;7:75-83.
9. Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated "acute phase response" in the brain? Immunol Today 1991;12:217-19.
10. Goldgaber D, Harris HW, Hla T, et al. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989;86:7606-10.
11. Licinio J, Wong M, Gold PW. Localization of interleukin-1 receptor antagonist mRNA in rat brain. Endocrinology 1991;129:562-4.
12. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991;12:404-10.
13. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992;29:243-6.
14. Cheng B, Christakos S, Mattson MP. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994;12:139-53.
15. Schwartz M, Solomon A, Lavie V, et al. Tumor necrosis factor facilitates regeneration of injured central nervous system axons. Brain Res 1991;545:334-8.
16. 2+ accumulation. Proc Natl Acad Sci USA 1995;92:9328-32.
17. Tarkowski E, Wallin A, Blennow K, et al. Local production of TNF-α, a potent neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999;19:223-30.
18. Tarkowski E, Liljeroth A-M, Nilsson Å, et al. TNF gene polymorphism and its relation to intracerebral production of TNF-α and -β in AD. Neurology 2000;54:2077-81.
19. Tarkowski E, Wallin A, Regland B, et al. Local and systemic cytokine release in patients with Alzheimer disease and vascular dementia. Acta Neurol Scan 2001;103:166-74.
20. Tarkowski E, Issa R, Sjögren M, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002;23:237-43.
21. (1-421) in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease. Arch Neurol 1999;56:673-80.
22. Andreasen N, Blennow K, Sjödin C, et al. Prevalens and Incidens of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Piteå Dementia project. Neuroepidemiology 1999;18:144-55.
23. Andreasen N, Minthon L, Vanmechelen F, et al. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999;273:5-8.
24. Folstein MF, Folstein SE, Mc Hugh P. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
25. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E, status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995;273:1274-8.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association, 1994.
27. Wollin A, Blennow K, Scheltens PH. Research criteria for clinical diagnosis of "pure" Alzheimer's disease. Drugs of Today 1994;30:265-73.
28. Mc Khann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
29. Blennow K, Wallin A, Ågren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26:231-45.
30. Vanderstichele H, Blennow K, D'Heuvaert N, et al. Development of a specific diagnostic test for measurement of b-amyloid(1-42) in CSF. In: Fisher A, Hanin I, Yoshida M, eds. Progress in Alzheimer's and Parkinson's diseases. New York: Plenum Press, 1998:773-8.
31. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
32. Benveniste EN, Tang LP, Law RM. Differential regulation of astrocyte TNF-α expression by the cytokines TGF-β, IL-6 and IL-10. Int J Dev Neurosci 1995;13:341-9.
33. Suzumara A, Sawada M, Yamamoto H, et al. Transforming growth factor-β suppresses activation and proliferation of microglia in vitro. J Immunol 1993;151:2150-8.
34. Tracey KJ. Tumor necrosis factor. In: Remick DG, Friedland JS, eds. Cytokines in health and disease. 2nd edn. NewYork: Marcel Dekker, 1997:223-39.
35. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease. Nature 1997;389:603-6.
36. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996;27:603-6.
37. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-β isoforms in human glioma cells in vitro. Cancer Letts 1996;102:209-15.
38. Krupinski J, Kumar P, Kumar S, et al. Increased expression of TGF-β1 in brain tissue after ischemic stroke in humans. Stroke 1996;27:852-7.
39. Behzadian MA, Wang X-L, Shabrawey M, et al. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-β. Glia 1998;24:216-25.
40. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer's disease. The nun study. JAMA 1997;277:813-17.
41. Andreasen N, Vanmechelen E, Van der Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow-up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
42. Galasko D, Chang L, Matter R, et al. High cerebrosplnal fluid tau and low amyloid beta 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genolype. Arch Neurol 1998;55:937-45.
43. Holmin S, Mathiesen T. Intracerebral administration of interleukin-1-beta induces neuronal DNA-fragmentation, encephalitis and vasogenic edema. J Neurosurgery 2000;92:108-20.
44. Sutton ET, Thomas T, Bryant MW, et al. Amyloid-beta peptide induced inflammatory reaction is mediated by the cytokines tumor necrosis factor and interleukin-1. J Submicrosc Cytol Pathol 1999;31:313-23.